Inhibition of ASBT Improves Liver Function in an Animal Model of Cholestatic Liver Disease
Data Presented Today at Annual Meeting of the American Association for the Study of Liver Diseases in Washington DC Provides Additional Preclinical Validation for LUM001 Currently Being Evaluated in Phase II Studies in Multiple Cholestatic Liver Disease Populations
SAN DIEGO – November 5, 2013 – Lumena Pharmaceuticals, a company developing oral therapeutics for cholestatic liver diseases, today announced that inhibition of the apical sodium-dependent bile acid transporter (ASBT) improves liver function in animal models of cholestasis. The data will be presented at 11:15 a.m. EST today in an oral presentation titled “SC-435, an Oral Inhibitor of ASBT, Improves Liver Function in a Rat Partial Bile Duct Ligation Model of Cholestasis,” at the 64th Annual Meeting of the American Association for the Study of Liver Diseases in Washington DC.
© 2019 Pappas Capital, LLC. ALL RIGHTS RESERVED.